Madrigal Pharmaceuticals (MDGL) logo

Madrigal Pharmaceuticals (MDGL) stock

Liver disease medicines , market cap $9.2B

$379.10
-4.45%

Why is MDGL down?

Down 8% on Nov 3, and still 12% under its Nov 2 close.

  • Its Nov 3 results: cost of sales was $37.8M, from $18.1M a year before. It fell 8% on Nov 3.

Sources: Price history, Nov 3, 2026; Company release, Nov 3, 2026

−2Long-term trend below a falling 200-day average, down over one year

Tell me next time MDGL moves

Free account, no card. An optional alert when MDGL moves or its score changes.Pro, $1 for a first month. An optional alert when MDGL moves or its score changes.Pro, 7 days free with a card. An optional alert when MDGL moves or its score changes.

Or see it live, free until Tuesday morning. No account.Or see one stock in full, free. No account.
1 more reason, free with an account →See every reason on MDGL →2 more reasons why MDGL fell on Nov 3, from its filings, with the other side, the timeline, and its peers, for Pro members.
Quality Score
1
Below Average
In its industry
#94of 273
Checks firing
1of 14
Transition
From 52-week high
-38.4%
under its best in a year

MDGL's Quality Score was unchanged on Fri, Nov 20, at 1.

Follow MDGL's trial news. Pro members can get an alert when Madrigal Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.

Get an alert when MDGL files news on its trialsSee it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Next1H 2027“Trial initiation is expected in the first half of 2027, subject to regulatory discussions.”Trial start · SEC filing · Nov 3
Cash$961M in cash. One of the last four quarters brought cash in while the others used it.On Sep 30 · the company says “into 2045”

Key facts on MDGL

Key facts on MDGL
Holding it backFree cash flow -$169M on $1.4B of sales
Latest filing8-K, Nov 3 Reported its quarterly results

What's next

Tue Dec 1: Evercore ISI 9th Annual HealthCONx…Investor conference · date confirmed.

1 more date ahead: the conference, for Pro members.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Cash$961M in cash. One of the last four quarters brought cash in while the others used it.On Sep 30 · the company says “into 2045”

MDGL catalysts

Coming up

After its last 4 reports it closed -5.4% on average, higher 1 of 4 times.

What's next for MDGL, and how long its cash lasts

Next step the company has named

1H 2027“Trial initiation is expected in the first half of 2027, subject to regulatory discussions.”Trial start · SEC filing · Nov 3

What it means: when a trial begins, or reaches the stage the company named.

A trial underway
Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)Phase 3 · Active · 845 people · main data estimated Dec 2026 · NCT05500222

6 more trials, 1 more milestone and 30 filings, for Pro members.

Cash runway Sep 30 balance sheet

$961M in cash

One of the last four quarters brought cash in while the others used it, so an average says little about the next.

What it means: a runway is counted only when each of the last four quarters used cash. The company's estimate is “into 2045” (8-K, May 6).

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3ASR, filed May 7, 2024)
  • At-the-market share sales program (S-3ASR, filed May 7, 2024)

For Pro members: 2 raises and their amounts, and the share count against a year ago.

Insiders

General Counsel Shannon T. Kelley sold 1,077 shares on Nov 6, under a planned sale. 22 more insider trades this year.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and William Sibold’s 10 filings and quotes.

Get an alert when MDGL files news on its trialsA free account. No card.Pro: $1 first month.Pro, 7 days free with a card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

12 more FDA dates and 98 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 144 dates, ranked →See all 144 dates, ranked →Start Pro

How MDGL ranks in Biotech

MDGL is #94 of 273 by Quality Score.

How MDGL ranks in Biotech
RankStockQuality Score
94Madrigal Pharmaceuticals (MDGL) logoMDGLMadrigal Pharmaceuticals1

Share count against a year before: MDGL +2.6%, XENE +26%, VKTX +5.1%.

More in Biotech

When does MDGL report earnings, and what happens after?

Expected to report Thu Feb 18, before the open (in 89 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What MDGL reported on Nov 3, 2026

The quarter

The figures are not read from the release yet.

“Third-quarter 2026 net revenues were $431.3 million, an increase of 50% compared to $287.3 million in the comparable prior year period, driven by increased demand for Rezdiffra in the U.S. in 2026.”

The filing on EDGAR

Where the sales came from

MDGL's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

In the company's words

  • “The increase in cost of sales was primarily driven by higher royalties payable to Roche as a result of increased net sales of Rezdiffra in 2026.”

From its results filing (SEC filing · Nov 3)

2 more sentences, for Pro members.

The numbers

Market value
$9.2B
today
Sales
$1.4B
up 92.8% on the year
Free cash flow
-$169M
last 12 months

Its share count grew 9.4% a year over 3 years.

4 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on MDGL: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

+7.4%-9.8%-8.1%
May 6Jul 30Nov 3
ReportedGapReaction5
days
Nov 3, 2026Before open+4.2%-8.1%+0.4%
Jul 30, 2026Before open-7.6%-9.8%-6.0%
May 6, 2026Before open+5.7%+7.4%+1.6%

MDGL closed higher after 1 of its last 4 reports.

All 4 reports, and MDGL's Quality Score going into each

MDGL sales and profit by year

Sales and profit by year

Sales grew in two of the last three years, to $958M in 2025. It lost money in each of the four years.

MDGL has 1 of 14 chart checks firing

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on MDGL, and all 14 on every stock.Get in free →See the top 3 →Start Pro

MDGL RSI on Nov 20: 26.2, below its 50-day and 200-day averages

Not scored

RSI 26.2, MACD below signal, below both averages. Not scored.

The deep dive on MDGL

  • What it does and how it makes money5 findingsAn operating loss of $300M in fiscal 2025, on $958M of sales.Annual report, filed Feb 19, 2026"In January 2026, we entered into an amendment to the Roche Agreement to provide us the full and exclusive right and discretion to control all patent term adjustments and patent term extensions applicable to Rezdiffra, including patents owned by Roche and jointly owned between the parties." (10-K for fiscal 2025)SEC filing · Feb 19, 2026
  • Where it stands3 findingsFor Pro members3 findings on where MDGL stands: its cash, debt, and share count, for Pro members
  • What changed in its filings7 findingsA new heading in its "Risk Factors" this year: "If we are unable to obtain or maintain adequate coverage and reimbursement from government or third-party payors for Rezdiffra or, if approved, any other product candidates, our prospects for generating revenue may be adversely affected." (10-K for fiscal 2025; not in fiscal 2024's)SEC filing · Feb 19, 2026, against the one of Feb 26, 2025One customer made up 34% of its revenue in fiscal 2025, down from 39% in fiscal 2024.SEC filing · Feb 19, 2026
  • Who holds and trades it2 findingsFor Pro members2 findings on who holds and trades MDGL, for Pro members
  • Against its closest peers2 peersShare count against a year before: MDGL +2.6%, XENE +26%, VKTX +5.1%.

13 more findings on MDGL, each with its source, for Pro members.

MDGL share count over time

Shares: 2.6% more than a year ago (to Sep 30).

Shares of MDGL outstanding, as filed
Shares
outstanding
As
of
23.2MOct 29, 2026
23.1MJul 27, 2026
23.1MMay 1, 2026
22.9MFeb 12, 2026
Offerings, shelves, and splits of MDGL, from its filings
From its
filings
Filed
Set up an at-the-market program for up to $300M of shares, about 3% of its market valueMay 7, 2024
Registered shares for a later sale (S-3ASR)May 7, 2024
Raised $195M in a sale of shares, about 2% of its market valueMar 20, 2024

MDGL insider trades

One insider bought $35M across 5 filings, and 2 insiders sold $1.7M across 11 filings, in the last 6 months. The newest:

BuyBaker Bros. Advisors LP$23.1MDirectorat $383.02 on Nov 6, filed Nov 6

All 16 insider filings on MDGL from the last six months, for Pro members.

All MDGL insider trades

MDGL's officers and directors

Officers and directors with a Form 4 in the last 12 months.

7 more officers and directors file at MDGL.

See insider trades by person

Which ETFs hold MDGL?

In ETFs: MDGL is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.

915 employeesWest Conshohocken, PAmadrigalpharma.com

What Madrigal Pharmaceuticals says it competes with

“The development and commercialization of drugs in MASH is highly competitive.”

From its annual report, SEC filing · Feb 19, 2026

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on MDGL and every other stock.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would turn MDGL's score around: 7 things
  • 5 more filings explained, a plain line each
  • 2 more things pulling MDGL's score down
BreakawayNov 6Baker Bros. Advisors LP bought MDGL$23.1M at $383.01, filed Nov 6

Alerts are optional.

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 21, 2026: MDGL's Quality Score is 1 (Below Average), #94 of 273 in Biotech. Insiders bought $35M and sold $1.7M in the last 6 months (Form 4).

What does MDGL's Quality Score say?

MDGL scores 1 today, which Breakaway calls Below Average. It is #94 of 273 in Biotech by Quality Score, with 1 of 14 chart checks firing. Down 8% on Nov 3, and still 12% under its Nov 2 close. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is MDGL's Quality Score?

MDGL scores 1 today, which Breakaway calls Below Average (0 to 5). That is #94 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind MDGL's 1.

Are insiders buying MDGL?

One insider bought $35M across 5 filings, and 2 insiders sold $1.7M across 11 filings, in the last 6 months. The newest is Baker Bros. Advisors LP, Director, who bought $23.1M on Nov 6. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,170 stocks rankedSee all 3,170 stocks rankedStart Pro

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

What's next for Madrigal Pharmaceuticals: from its SEC filings and ClinicalTrials.gov, the company's words, the registry's dates, and arithmetic, not a forecast. Companies often miss the dates they set.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.